{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T03:15:31Z","timestamp":1790306131224,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.rmed.2024.107720","type":"journal-article","created":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T13:13:42Z","timestamp":1720530822000},"page":"107720","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Dupilumab responder types and predicting factors in patients with type 2 severe asthma: A real-world cohort study"],"prefix":"10.1016","volume":"231","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-1835-3195","authenticated-orcid":false,"given":"L.","family":"Bult","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.C.","family":"Thelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3627-6925","authenticated-orcid":false,"given":"S.P.","family":"Rauh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.C.C.M. in \u2018t","family":"Veen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7671-3742","authenticated-orcid":false,"given":"G.J.","family":"Braunstahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.rmed.2024.107720_bib2","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jaci.2014.08.042","article-title":"The prevalence of severe refractory asthma","volume":"135","author":"Hekking","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.rmed.2024.107720_bib3","article-title":"The prevalence and clinical characteristics of T2-high and T2-low endotype of severe uncontrolled asthma distinguished by combining popular type-2 biomarkers","volume":"54","author":"Oishi","year":"2019","journal-title":"Eur. Respir. J."},{"issue":"3","key":"10.1016\/j.rmed.2024.107720_bib4","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.jaip.2020.09.051","article-title":"The prevalence of subtypes of type 2 inflammation in an unselected population of patients with severe asthma","volume":"9","author":"Frossing","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"1","key":"10.1016\/j.rmed.2024.107720_bib5","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nri3786","article-title":"Type 2 inflammation in asthma--present in most, absent in many","volume":"15","author":"Fahy","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.rmed.2024.107720_bib6","author":"Asthma"},{"issue":"9","key":"10.1016\/j.rmed.2024.107720_bib7","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1111\/j.1365-2222.2005.02314.x","article-title":"The use of exhaled nitric oxide concentration to identify eosinophilic airway inflammation: an observational study in adults with asthma","volume":"35","author":"Berry","year":"2005","journal-title":"Clin. Exp. Allergy"},{"issue":"5","key":"10.1016\/j.rmed.2024.107720_bib8","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1080\/1744666X.2017.1298443","article-title":"Commonality of the IL-4\/IL-13 pathway in atopic diseases","volume":"13","author":"Gandhi","year":"2017","journal-title":"Expet Rev. Clin. Immunol."},{"issue":"5","key":"10.1016\/j.rmed.2024.107720_bib9","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/all.14151","article-title":"Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Ralpha antibody, is required to broadly inhibit type 2 inflammation","volume":"75","author":"Le Floc'h","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.rmed.2024.107720_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2022.107058","article-title":"Efficacy and safety of dupilumab as add-on therapy for patients with severe asthma: a real-world Dutch cohort study","volume":"206","author":"Thelen","year":"2023","journal-title":"Respir. Med."},{"issue":"10039","key":"10.1016\/j.rmed.2024.107720_bib11","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(16)30307-5","article-title":"Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting beta2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial","volume":"388","author":"Wenzel","year":"2016","journal-title":"Lancet"},{"issue":"26","key":"10.1016\/j.rmed.2024.107720_bib12","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.rmed.2024.107720_bib13","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.rmed.2024.107720_bib14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S2213-2600(21)00322-2","article-title":"Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study","volume":"10","author":"Wechsler","year":"2022","journal-title":"Lancet Respir. Med."},{"issue":"8","key":"10.1016\/j.rmed.2024.107720_bib15","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1111\/all.15747","article-title":"Dupilumab improves long-term outcomes in patients with uncontrolled, moderate-to-severe GINA-based type 2 asthma, irrespective of allergic status","volume":"78","author":"Rabe","year":"2023","journal-title":"Allergy"},{"issue":"5","key":"10.1016\/j.rmed.2024.107720_bib16","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s12325-018-0702-4","article-title":"Liberty asthma QUEST: phase 3 randomized, double-blind, placebo-controlled, parallel-group study to evaluate dupilumab efficacy\/safety in patients with uncontrolled, moderate-to-severe asthma","volume":"35","author":"Busse","year":"2018","journal-title":"Adv. Ther."},{"key":"10.1016\/j.rmed.2024.107720_bib17","first-page":"A5995","article-title":"Dupilumab induces clinical remission in patients with uncontrolled, moderate-to-severe","volume":"207","author":"Pavord","year":"2023","journal-title":"Type 2 Inflamm. Asthma (abstract)."},{"key":"10.1016\/j.rmed.2024.107720_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2023.107348","article-title":"Severe asthma clinical remission after biologic treatment with anti-IL4\/IL13: a real-life experience","volume":"217","author":"Portacci","year":"2023","journal-title":"Respir. Med."},{"key":"10.1016\/j.rmed.2024.107720_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1121237","article-title":"Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polyps","volume":"14","author":"Pelaia","year":"2023","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.rmed.2024.107720_bib20","doi-asserted-by":"crossref","DOI":"10.1002\/clt2.12081","article-title":"Reduced exacerbation frequency and prednisone dose in patients with ABPA and asthma treated with dupilumab","volume":"11","author":"van der Veer","year":"2021","journal-title":"Clin. Transl. Allergy"},{"issue":"3","key":"10.1016\/j.rmed.2024.107720_bib21","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jaci.2019.12.006","article-title":"An expert consensus framework for asthma remission as a treatment goal","volume":"145","author":"Menzies-Gow","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"issue":"3","key":"10.1016\/j.rmed.2024.107720_bib22","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.jaip.2020.10.010","article-title":"Long-Term therapy response to anti-IL-5 biologics in severe asthma-A real-life evaluation","volume":"9","author":"Eger","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"11","key":"10.1016\/j.rmed.2024.107720_bib23","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1016\/j.jaip.2021.06.041","article-title":"Defining a severe asthma super-responder: findings from a delphi process","volume":"9","author":"Upham","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"5","key":"10.1016\/j.rmed.2024.107720_bib24","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1007\/s12325-022-02098-1","article-title":"Clinical remission in severe asthma: a pooled post hoc analysis of the patient journey with benralizumab","volume":"39","author":"Menzies-Gow","year":"2022","journal-title":"Adv. Ther."},{"issue":"5","key":"10.1016\/j.rmed.2024.107720_bib25","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02583-2021","article-title":"Asthma remission: what is it and how can it be achieved?","volume":"60","author":"Thomas","year":"2022","journal-title":"Eur. Respir. J."},{"issue":"5","key":"10.1016\/j.rmed.2024.107720_bib26","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.rmed.2004.10.008","article-title":"Measurement properties and interpretation of three shortened versions of the asthma control questionnaire","volume":"99","author":"Juniper","year":"2005","journal-title":"Respir. Med."},{"issue":"1","key":"10.1016\/j.rmed.2024.107720_bib27","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01499-2021","article-title":"ERS\/ATS technical standard on interpretive strategies for routine lung function tests","volume":"60","author":"Stanojevic","year":"2022","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.rmed.2024.107720_bib28","doi-asserted-by":"crossref","first-page":"W1","DOI":"10.7326\/M14-0698","article-title":"Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration","volume":"162","author":"Moons","year":"2015","journal-title":"Ann. Intern. Med."},{"issue":"6","key":"10.1016\/j.rmed.2024.107720_bib31","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1080\/02770903.2019.1591443","article-title":"Treat to target approach for asthma","volume":"57","author":"Nannini","year":"2020","journal-title":"J. Asthma"},{"issue":"207","key":"10.1016\/j.rmed.2024.107720_bib32","article-title":"Dupilumab induces clinical remission in patients with uncontrolled, moderate-to-severe","author":"Pavord","year":"2023","journal-title":"Type 2 Inflamm. Asthma."},{"key":"10.1016\/j.rmed.2024.107720_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2024.107528","article-title":"Comparison of clinical remission criteria for severe asthma patients receiving biologic therapy","volume":"222","author":"Breslavsky","year":"2024","journal-title":"Respir. Med."},{"key":"10.1016\/j.rmed.2024.107720_bib34","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2147\/JAA.S357548","article-title":"Real-world effectiveness of dupilumab for patients with severe asthma: a retrospective study","volume":"15","author":"Numata","year":"2022","journal-title":"J. Asthma Allergy"},{"issue":"11","key":"10.1016\/j.rmed.2024.107720_bib35","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1016\/j.jaip.2022.06.036","article-title":"Dupilumab is effective in patients with moderate-to-severe uncontrolled GINA-defined type 2 asthma irrespective of an allergic asthma phenotype","volume":"10","author":"Rabe","year":"2022","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"4","key":"10.1016\/j.rmed.2024.107720_bib36","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.04605-2020","article-title":"Impact of baseline patient characteristics on dupilumab efficacy in type 2 asthma","volume":"58","author":"Busse","year":"2021","journal-title":"Eur. Respir. J."},{"issue":"60","key":"10.1016\/j.rmed.2024.107720_bib37","article-title":"Clinical response and remission in patients with severe asthma treated with biologic treatment: findings from the nationwide Danish Severe Asthma Registry","author":"Hansen","year":"2022","journal-title":"Eur. Respir. J."},{"issue":"2","key":"10.1016\/j.rmed.2024.107720_bib38","doi-asserted-by":"crossref","first-page":"219","DOI":"10.4168\/aair.2021.13.2.219","article-title":"Sex differences in severe asthma: results from severe asthma network in Italy-sani","volume":"13","author":"Senna","year":"2021","journal-title":"Allergy Asthma Immunol. Res."},{"issue":"suppl 65","key":"10.1016\/j.rmed.2024.107720_bib39","article-title":"Sex differences in severe asthma","volume":"58","author":"Azim","year":"2021","journal-title":"Eur. Respir. J."},{"issue":"4","key":"10.1016\/j.rmed.2024.107720_bib40","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.jaip.2022.02.002","article-title":"Personalized treatment of asthma: the importance of sex and gender differences","volume":"10","author":"Jenkins","year":"2022","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"3","key":"10.1016\/j.rmed.2024.107720_bib41","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1164\/rccm.200711-1754OC","article-title":"Cluster analysis and clinical asthma phenotypes","volume":"178","author":"Haldar","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"4","key":"10.1016\/j.rmed.2024.107720_bib42","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.jaip.2022.11.043","article-title":"Baseline FeNO independently predicts the dupilumab response in patients with moderate-to-severe asthma","volume":"11","author":"Pavord","year":"2023","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"1","key":"10.1016\/j.rmed.2024.107720_bib43","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.2500\/aap.2024.45.230072","article-title":"Real-world effectiveness and predictors of super-responders to dupilumab in a Chinese uncontrolled asthma cohort","volume":"45","author":"Chen","year":"2024","journal-title":"Allergy Asthma Proc."},{"issue":"8","key":"10.1016\/j.rmed.2024.107720_bib44","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1164\/rccm.202310-1751LE","article-title":"Biomarkers associated with lung function decline and dupilumab response in patients with asthma","volume":"209","author":"Pavord","year":"2024","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"2","key":"10.1016\/j.rmed.2024.107720_bib45","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.chest.2020.08.2083","article-title":"Real-world effectiveness of benralizumab in severe eosinophilic asthma","volume":"159","author":"Kavanagh","year":"2021","journal-title":"Chest"},{"issue":"8","key":"10.1016\/j.rmed.2024.107720_bib46","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12082900","article-title":"A real-world study of achievement rate and predictive factors of clinical and deep remission to biologics in patients with severe asthma","volume":"12","author":"Oishi","year":"2023","journal-title":"J. Clin. Med."},{"issue":"4","key":"10.1016\/j.rmed.2024.107720_bib47","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00238-2022","article-title":"Complete response to anti-interleukin-5 biologics in a real-life setting: results from the nationwide Danish Severe Asthma Register","volume":"8","author":"Soendergaard","year":"2022","journal-title":"ERJ Open Res."},{"issue":"2","key":"10.1016\/j.rmed.2024.107720_bib48","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.chest.2020.03.042","article-title":"Real-world effectiveness and the characteristics of a \"Super-Responder\" to mepolizumab in severe eosinophilic asthma","volume":"158","author":"Kavanagh","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2024.107720_bib49","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.2147\/JAA.S340684","article-title":"Feasibility of discontinuing biologics in severe asthma: an algorithmic approach","volume":"14","author":"Hamada","year":"2021","journal-title":"J. Asthma Allergy"}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611124001951?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611124001951?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T23:20:40Z","timestamp":1722640840000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611124001951"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":46,"alternative-id":["S0954611124001951"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2024.107720","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dupilumab responder types and predicting factors in patients with type 2 severe asthma: A real-world cohort study","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2024.107720","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107720"}}